Trevi Therapeutics Inc (TRVI)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $1.89B
Last updated: Nov 17, 2026 at 4:20 PM ET
Trevi Therapeutics Inc (TRVI) Stock Chart
Trevi Therapeutics (TRVI) has a latest price of $13.51 on Nov 17, 2026, 33.2% below its 52-week high of $20.22. Its price rose 18.8% over the past 12 months. The month-end price rose 1,054.0% over the 5 years through Oct 2026, a compound annual rate of 63.1%.
Price Chart
From May 2019 to Oct 2026, its highest month-end close was $18.65 in Jun 2026 and its lowest $0.64 in Jan 2022, adjusted for splits.
Month-end closes, adjusted for splits. Dividends are not included.
Chart TRVI with Advanced Charting
Daily candlesticks, valuation multiples, side-by-side comparisons and drawings for TRVI.
Free with a GNG account. No credit card.
Price Performance
Over the past 3 months the price fell 28.2%, and over 6 months it rose 2.0%. The month-end price rose 661.8% over the 3 years through Oct 2026, a compound annual rate of 96.8%.
| Period | Change |
|---|---|
| 1 month | +13.5% |
| 3 months | -28.2% |
| 6 months | +2.0% |
| 12 months | +18.8% |
| 12 months, with dividends | +18.8% |
| Period | Change | Per year |
|---|---|---|
| 3 years | +661.8% | +96.8% |
| 5 years | +1,054.0% | +63.1% |
Price by Year
Its best calendar year was 2024, when the price rose 207.5%, and its weakest was 2021, when it fell 67.7%.
| Year | Close | Change |
|---|---|---|
| 2026 through Oct 2026 | $13.56 | +8.3% |
| 2025 | $12.52 | +203.9% |
| 2024 | $4.12 | +207.5% |
| 2023 | $1.34 | -30.6% |
| 2022 | $1.93 | +146.7% |
| 2021 | $0.78 | -67.7% |
| 2020 | $2.42 | -35.5% |
Trading Range
The price is 2.7% below its 50-day average of $13.89 and 7.1% below its 200-day average of $14.55.
| Measure | Value | Price vs |
|---|---|---|
| Latest price (Nov 17, 2026) | $13.51 | |
| 52-week high | $20.22 | -33.2% |
| 52-week low | $9.82 | +37.6% |
| 50-day average | $13.89 | -2.7% |
| 200-day average | $14.55 | -7.1% |
Price Risk
Over 3 years, its largest fall from a peak was 39.1%.
| Measure | Value |
|---|---|
| 1-year beta | 1.37 |
| Largest fall, 1 year | -39.1% |
| Largest fall, 3 years | -39.1% |
Advanced Charting Features
Advanced Charting is free with a GNG account, and signed-in members get it in place of the price chart above.
- Valuation multiples. Daily P/E, price to sales, cash flow and book value, PEG and PEGY, drawn behind the price wherever the company's data supports them.
- Price charts and drawings. Candlestick, OHLC, line and area charts with volume and earnings, dividend and split markers, plus trend lines, levels and notes kept in your account.
- Side-by-side compare. Two stocks next to each other on one metric and time span, each chart with its own price scale.
- Projections and saved views. Pick a start and an end point to see the price return, dividends and total return between them, and save views to open later.
Frequently Asked Questions About TRVI
What is TRVI's 1-year price change?
Trevi Therapeutics's price rose 18.8% over the past 12 months. With dividends included, the 12-month total return was 18.8%.
What is TRVI's 5-year price change?
Trevi Therapeutics's month-end price rose 1,054.0% over the 5 years through Oct 2026, a compound annual rate of 63.1%. These figures leave out dividends.
What is TRVI's 52-week high and low?
Trevi Therapeutics's 52-week high is $20.22 and its 52-week low is $9.82. Its latest price of $13.51 on Nov 17, 2026 is 33.2% below the high.
What is TRVI's beta?
Trevi Therapeutics's 1-year beta against the S&P 500 is 1.37, so its price has moved more than the market over the past year. Its largest fall from a peak over the past year was 39.1%.
Is the TRVI chart free?
Yes. Advanced Charting for TRVI is free with a GNG account, and no credit card is needed. It adds daily candlestick and line charts with volume, valuation multiples, side-by-side comparisons, drawings and saved views.
TRVI pages: Overview, Charting, Earnings, Forecast, Financials, Statistics, Competitors